CommercialPrior AuthHigh impact
Adalimumab (CPB 0655, reviewed 2026-07-13)
Aetna·Rheumatology, Dermatology, Gastroenterology +3 more·Medical Policy
Effective date
Jul 13, 2026
We identified it
Aug 17, 2026
Summary
Aetna has updated its Clinical Policy Bulletin 0655 for adalimumab and its 11 biosimilar products (effective 2026-07-13), establishing comprehensive prior authorization and medical necessity criteria across 10 indications. The policy specifies prescriber specialty requirements, biomarker testing mandates for rheumatoid arthritis, trial-and-failure sequences for conventional synthetic drugs, and age-specific requirements for pediatric indications. Billing teams must implement these criteria in prior authorization workflows to prevent claim denials.
Action Required
By 2026-07-13, the billing and prior authorization team must: (1) Update the authorization system to require prescriber specialty verification (rheumatologist, dermatologist, gastroenterologist, ophthalmologist, oncologist, or hematologist based on indication) before approving adalimumab claims; (2) Configure the system to enforce biomarker testing documentation requirements for RA cases (RF, anti-CCP, and/or CRP/ESR results); (3) Implement trial-and-failure logic requiring documented evidence of prior conventional synthetic drug trials (methotrexate monotherapy at ≥15 mg/week for 3 months minimum) for RA, PsA, AS, and nr-axSpA indications; (4) For hidradenitis suppurativa, require proof of ≥8 weeks oral antibiotic trial or documented intolerance before approval; (5) Add age restrictions to authorization rules (JIA minimum age 2 years, hidradenitis suppurativa minimum age 12 years); (6) Create separate authorization pathways for members with prior biologic/targeted synthetic drug exposure (approval within 120 days for RA, AS, nr-axSpA, PsA, PsO; any prior biologic for JIA, hidradenitis suppurativa, uveitis); (7) For plaque psoriasis, configure criteria requiring either crucial body area involvement, ≥10% BSA affected, or ≥3% BSA with prior phototherapy/pharmacologic trial failure; (8) Update prior authorization denial templates to reference specific failed treatment requirements. Failure to implement these criteria will result in claim denials and patient appeals. Communicate updated requirements to all in-network providers in rheumatology, dermatology, gastroenterology, and ophthalmology specialties.